Regeneron Pharmaceuticals Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Regeneron Pharmaceuticals, Inc. has submitted its quarterly 10-Q filing for the period ending March 31, 2024, detailing financial performance and position.</b>

AI Summary

REGENERON PHARMACEUTICALS, INC. (REGN) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Regeneron Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of fiscal year 2024. The company's principal business is the discovery, development, manufacturing, and sale of pharmaceutical products. The filing includes financial data for the periods ending March 31, 2024, December 31, 2023, and March 31, 2023. Key financial statement components such as Common Stock, Additional Paid-In Capital, Retained Earnings, and Treasury Stock are detailed for various periods.

Why It Matters

For investors and stakeholders tracking REGENERON PHARMACEUTICALS, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial performance data for Regeneron, crucial for assessing the company's current health and future prospects. The detailed financial statements and disclosures within the report are essential for understanding revenue streams, equity structure, and changes in financial position over the reported periods.

Risk Assessment

Risk Level: low — REGENERON PHARMACEUTICALS, INC. shows low risk based on this filing. The risk is low as this is a standard quarterly filing (10-Q) providing routine financial updates, not indicating any immediate or significant adverse events.

Analyst Insight

Review the detailed financial statements and segment information within the 10-Q to understand revenue trends and changes in the company's financial position.

Key Numbers

• 2024-03-31 — Reporting Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-05-02 — Filing Date (FILED AS OF DATE)
• 12/31 — Fiscal Year End (FISCAL YEAR END)
• 2024-01-01 — Quarter Start Date (2024-01-01)
• 2024-03-31 — Quarter End Date (2024-03-31)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — FILER
• REGN (company) — tk
• 2024-05-02T00:00:00.000Z (date) — dt
• 2024-03-31 (date) — CONFORMED PERIOD OF REPORT
• 0000872589 (company) — CENTRAL INDEX KEY
• 2834 (industry) — STANDARD INDUSTRIAL CLASSIFICATION
• NY (location) — STATE OF INCORPORATION
• TARRYTOWN (location) — CITY

FAQ

Industry Context

Regeneron Pharmaceuticals operates within the pharmaceutical industry, focusing on the discovery, development, manufacturing, and sale of pharmaceutical products.

Regulatory Implications

As a publicly traded pharmaceutical company, Regeneron is subject to regulations from the Securities and Exchange Commission (SEC) for financial reporting, including the filing of 10-Q forms.

What Investors Should Do

1. Analyze the financial statements for the three months ended March 31, 2024, and compare them to the same period in 2023.
2. Review the changes in equity accounts, such as Common Stock and Retained Earnings, between December 31, 2023, and March 31, 2024.
3. Identify any new disclosures or updates in the business description or risk factors section, although none were explicitly detailed in the header.

Year-Over-Year Comparison

This filing represents the first quarterly report for the fiscal year 2024, providing updated financial information compared to the previous year's filings.

Filing Documents

• regn-20240331.htm (10-Q) — 1660KB
• regn-ex_101x03312024x10q.htm (EX-10.1) — 17KB
• regn-ex_311x03312024x10q.htm (EX-31.1) — 12KB
• regn-ex_312x03312024x10q.htm (EX-31.2) — 12KB
• regn-ex_32x03312024.htm (EX-32) — 7KB
• 0001804220-24-000017.txt (&nbsp;) — 6800KB
• regn-20240331.xsd (EX-101.SCH) — 40KB
• regn-20240331_cal.xml (EX-101.CAL) — 61KB
• regn-20240331_def.xml (EX-101.DEF) — 246KB
• regn-20240331_lab.xml (EX-101.LAB) — 477KB
• regn-20240331_pre.xml (EX-101.PRE) — 367KB
• regn-20240331_htm.xml (XML) — 970KB

Financial Statements (unaudited)

Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations and Comprehensive Income 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 43 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77 Item 5. Other Information 77 Item 6. Exhibits 78 SIGNATURE PAGE 79 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD," "Inmazeb ," "Libtayo ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," " Veloci-Bi ," " VelociGene ," " VelociHum ," " VelociMab ," " VelocImmune ," " VelociMouse ," " VelociSuite ," " VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions, except per share data) March 31, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 2,602.0 $ 2,730.0 Marketable securities 7,917.5 8,114.8 Accounts receivable, net 5,222.2 5,667.3 Inventories 2,714.9 2,580.5 Prepaid expenses and other current assets 414.9 386.6 Total current assets 18,871.5 19,479.2 Marketable securities 6,978.8 5,396.5 Property, plant, and equipment, net 4,225.5 4,146.4 Intangible assets, net 1,058.7 1,038.6 Deferred tax assets 2,764.9 2,575.4 Other noncurrent assets 470.2 444.1 Total assets $ 34,369.6 $ 33,080.2 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 671.3 $ 606.6 Accrued expenses and other current liabilities 2,392.9 2,357.9 Deferred revenue 516.7 458.9 Total current liabilities 3,580.9 3,423.4 Long-term debt 1,983.3 1,982.9 Finance lease liabilities 720.0 720.0 Deferred revenue 185.8 126.7 Other noncurrent liabilities 908.5 854.1 Total liabilities 7,378.5 7,107.1 Stockholders' equity: Preferred Stock, par value $ .01 per share; 30.0 shares authorized; shares issued and outstanding - no ne — — Class A Stock, convertible, par value $ .001 per share; 40.0 shares authorized; shares issued and outstanding - 1.8 in 2024 and 2023 — — Common Stock, par value $ .001 per share; 320.0 shares authorized; shares issued - 134.2 in 2024 and 133.1 in 2023 0.1 0.1 Additional paid-in capital 11,942.6 11,354.0 Retained earnings 27,982.3 27,260.3 Accumulated other comprehensive loss ( 77.2 ) ( 80.9 ) Treasury Stock, at cost; 25.8 shares in 2024 and 25.5 shares in 2023 ( 12,856.7 ) ( 12,560.4 ) Total stockholders' equity 26,991.1 25,973.1 Total liabilities and stockholders' equity $ 34,369.6 $ 33,080.2 The accompanying notes are an integral part of the financial statements. 2 Table of Contents REGENERON PHARMACEUTICALS, INC.

View Full Filing

View this 10-Q filing on SEC EDGAR